Novocure Capex To Revenue from 2010 to 2024

NVCR Stock  USD 18.78  1.05  5.92%   
Novocure Capex To Revenue yearly trend continues to be relatively stable with very little volatility. Capex To Revenue is likely to drop to 0.05. Capex To Revenue is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. View All Fundamentals
 
Capex To Revenue  
First Reported
2010-12-31
Previous Quarter
0.05319258
Current Value
0.0505
Quarterly Volatility
0.143093
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Novocure financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novocure's main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.8 M, Interest Expense of 7.7 M or Selling General Administrative of 87.6 M, as well as many indicators such as Price To Sales Ratio of 2.96, Dividend Yield of 0.0 or PTB Ratio of 4.16. Novocure financial statements analysis is a perfect complement when working with Novocure Valuation or Volatility modules.
  
Check out the analysis of Novocure Correlation against competitors.
To learn how to invest in Novocure Stock, please use our How to Invest in Novocure guide.

Latest Novocure's Capex To Revenue Growth Pattern

Below is the plot of the Capex To Revenue of Novocure over the last few years. It is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. Novocure's Capex To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novocure's overall financial position and show how it may be relating to other accounts over time.
Capex To Revenue10 Years Trend
Slightly volatile
   Capex To Revenue   
       Timeline  

Novocure Capex To Revenue Regression Statistics

Arithmetic Mean0.16
Geometric Mean0.1
Coefficient Of Variation89.77
Mean Deviation0.13
Median0.05
Standard Deviation0.14
Sample Variance0.02
Range0.3231
R-Value(0.87)
Mean Square Error0.01
R-Squared0.75
Significance0.00003
Slope(0.03)
Total Sum of Squares0.29

Novocure Capex To Revenue History

2024 0.0505
2023 0.0532
2022 0.0397
2021 0.0452
2020 0.0303
2019 0.0298
2018 0.0271

About Novocure Financial Statements

Novocure shareholders use historical fundamental indicators, such as Capex To Revenue, to determine how well the company is positioned to perform in the future. Although Novocure investors may analyze each financial statement separately, they are all interrelated. The changes in Novocure's assets and liabilities, for example, are also reflected in the revenues and expenses on on Novocure's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Capex To Revenue 0.05  0.05 

Additional Tools for Novocure Stock Analysis

When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.